The authors have no financial interests in this article. EG: congress fees and investigator for Novartis and Pierre Fabre Dermatology. FD, MBB, APL, VH, MSJ, SA, MTL, AK, and BD have no conflict of interest. CD: congress fees, consulting, boards and investigation on trials for Novartis and Pierre Fabre Oncology. GQ: congress fees, investigator, board member, or consultant for BMS, Regeneron, MSD, Pfizer, Novartis, Pierre Fabre oncology and Sanofi. MA: has received fees from BMS, Pierre Fabre oncology, Sanofi and Sun Pharma for advisory board, financial support for congress participation. FA is board member or consultant or received payment for development of educational presentations and including travel/accommodations expenses covered or reimbursed from Abbvie, Amgen, Almirall, MSD, BMS, Pfizer, Abbott, Janssen-Cilag, Galderma, Leo Pharma, Medac, Galderma, Kiowa Kirin Pharma, UCB, Novartis, Sanofi, Takeda, La Roche Posay, Sun Pharma, Uriage, Viatris. ChN is a consultant or member of advisory boards with BMS, MSD and Novartis and has received financial support for travel and accommodation expenses from BMS, MSD and Novartis. SM: Pierre Fabre et novartis, advisory Board and congress fees. SP: congress fees and investigator for Novartis and Pierre Fabre Dermatology.

This study adheres to the ethical standards outlined in the Declaration of Helsinki. The research protocol was approved by the institutional review board, and all participants provided informed consent. Confidentiality and privacy of the subjects were maintained throughout the study.